Christopher M. Adams, MD, PhD – Founder, President, and CEO
Chris Adams has served as President and CEO of Emmyon since its inception in 2012. He is also a physician-scientist and a Professor of Medicine and the Fraternal Order of Eagles Diabetes Research Chair at the University of Iowa. After receiving his MD and PhD degrees from University of Iowa in 1999, Chris moved to the University of Texas Southwestern Medical Center, where he completed an internship and residency in Internal Medicine, a fellowship in Endocrinology and Metabolism, and five years of post-doctoral research training with Nobel laureates Drs. Michael Brown and Joseph Goldstein. In 2006, Chris was recruited back to the University of Iowa, where he was promoted to an endowed chair in 2017. His clinical practice focuses on the care of patients with diabetes and other endocrine disorders. His research has primarily focused on the problem of skeletal muscle atrophy. He was elected to the American Society for Clinical Investigation in 2013 and serves as a standing member of the Skeletal Muscle Biology and Exercise Physiology study section at the National Institutes of Health. He is lead inventor on 6 issued patents, 3 allowed patents, and 14 pending patent applications, all exclusively licensed to Emmyon.
Scott M. Ebert, PhD – Senior Research Scientist
Scott Ebert joined Emmyon as a Research Scientist in 2013. Prior to joining Emmyon, he completed his PhD in Molecular and Cellular Biology and post-doctoral training with Chris Adams at the University of Iowa. Scott has authored 12 peer-reviewed publications concerning molecular mechanisms of skeletal muscle atrophy, and he has played a central role in the development of ursolic acid, tomatidine, and other small molecules that are being developed at Emmyon. Scott has also been the lead principal investigator on three SBIR/STTR awards to Emmyon from the NIH.
Michael C. Dyle, PhD – Research Scientist
Mike Dyle joined Emmyon as a Research Scientist in 2016. Prior to joining Emmyon, he completed his PhD in Molecular Physiology and Biophysics and post-doctoral training with Chris Adams at the University of Iowa. Mike has authored 9 peer-reviewed publications concerning molecular mechanisms of skeletal muscle atrophy, and he has played a key role in the development of tomatidine and other small molecules that are being developed at Emmyon.
John J. Talley, PhD – Senior Scientific Advisor
John Talley has served as a senior scientific advisor and led the medicinal chemistry program at Emmyon since its inception in 2012. He is one of the world’s most accomplished medicinal chemists and an inventor on more than 200 issued U.S. patents. For example, he is the lead inventor of several commercial medicines including the COX-2 specific inhibitors Celebrex®, Bextra®, Dynastat®, Deramaxx® and Trocoxil®. John received the prestigious PhRMA Discoverers Award in 2002 for the discovery of Celebrex®. He is also co-inventor of the hydroxyethyl sulfonamide class of inhibitors for the treatment of HIV/AIDS, marketed under the brand names of Agenerase® , Telzir® , and Prezista®. Altogether, the approved drugs invented by John have resulted in >$40 billion in sales. In 2015 and 2016, John was named by The Medicine Maker magazine as one the world’s 20 most influential people in drug discovery and development.
Michael J. Welsh, MD – Senior Scientific Advisor
Mike Welsh helped to found Emmyon in 2012 and has served as a senior scientific advisor since Emmyon’s inception. He is also a physician-scientist, a Howard Hughes Medical Institute (HHMI) Investigator, and a Professor of Medicine and the Director of the Pappajohn Biomedical Institute at the University of Iowa. Mike became an HHMI Investigator in 1989. He has served as President of the American Society for Clinical Investigation and the Association of American Physicians. He was elected to the Institute of Medicine (1997), the American Academy of Arts and Sciences (1998), and the National Academy of Sciences (2000).
Hayden J. Trubitt, JD – Outside Legal Advisor
Hayden Trubitt has been outside legal advisor for Emmyon since its founding in 2012. He is a shareholder in the corporate law practice of Stradling Yocca Carlson & Rauth, P.C., San Diego, California. He received his JD, magna cum laude, in 1979 from Harvard Law School, where he was a senior editor of the Harvard Law Review. His fellow law review editors included John Roberts, now Chief Justice of the United States. Mr. Trubitt has practiced corporate law in San Diego for more than 35 years, and was one of the pioneers in representing emerging company issuers in that region.
Philip E. Hansen, PhD – Outside Patent Advisor
Phil Hansen is outside patent advisor for Emmyon. He is a registered patent agent in the intellectual property firm of Heslin Rothenberg Farley & Mesiti P.C., Albany, New York. His background includes 16 years of experience as a research chemist in the pharmaceutical industry and 28 years as a patent agent. Phil earned his PhD in Chemistry at Cornell.
Erica M. Hines, MBA, JD – Outside Patent Counsel
Erica Hines is outside patent counsel for Emmyon. She is a registered patent attorney with Heslin Rothenberg Farley & Mesiti P.C., Albany, New York. Erica received her JD, magna cum laude, from Albany Law School, and is Immediate Past Chairperson of the Young Lawyers Section of the New York State Bar Association.